Abstract
The alpha emitters 225Ac and 213Bi are promising therapeutic radionuclides for application in targeted alpha therapy of cancer and infectious diseases. Both alpha emitters are available with high specific activity from established radionuclide generators. Their favourable chemical and physical properties have led to the conduction of a large number of preclinical studies and several clinical trials, demonstrating the feasibility, safety and therapeutic efficacy of targeted alpha therapy with 225Ac and 213Bi. This review describes methods for the production of 225Ac and 213Bi and gives an overview of 225Ac/213Bi radionuclide generator systems. Selected preclinical studies are highlighted and the current clinical experience with 225Ac and 213Bi is summarized.
Keywords: Targeted alpha therapy, Alpha emitter, Actinium-225, Bismuth-213, Preclinical, Clinical studies, DOTA-biotin, xenografts, DOTATOC, AMBA
Current Radiopharmaceuticals
Title:Bismuth-213 and Actinium-225 – Generator Performance and Evolving Therapeutic Applications of Two Generator-Derived Alpha-Emitting Radioisotopes
Volume: 5 Issue: 3
Author(s): Alfred Morgenstern, Frank Bruchertseifer and Christos Apostolidis
Affiliation:
Keywords: Targeted alpha therapy, Alpha emitter, Actinium-225, Bismuth-213, Preclinical, Clinical studies, DOTA-biotin, xenografts, DOTATOC, AMBA
Abstract: The alpha emitters 225Ac and 213Bi are promising therapeutic radionuclides for application in targeted alpha therapy of cancer and infectious diseases. Both alpha emitters are available with high specific activity from established radionuclide generators. Their favourable chemical and physical properties have led to the conduction of a large number of preclinical studies and several clinical trials, demonstrating the feasibility, safety and therapeutic efficacy of targeted alpha therapy with 225Ac and 213Bi. This review describes methods for the production of 225Ac and 213Bi and gives an overview of 225Ac/213Bi radionuclide generator systems. Selected preclinical studies are highlighted and the current clinical experience with 225Ac and 213Bi is summarized.
Export Options
About this article
Cite this article as:
Morgenstern Alfred, Bruchertseifer Frank and Apostolidis Christos, Bismuth-213 and Actinium-225 – Generator Performance and Evolving Therapeutic Applications of Two Generator-Derived Alpha-Emitting Radioisotopes, Current Radiopharmaceuticals 2012; 5 (3) . https://dx.doi.org/10.2174/1874471011205030221
DOI https://dx.doi.org/10.2174/1874471011205030221 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Delivering RNA Interference to the Mammalian Brain
Current Gene Therapy Radiosensitizing Potential of Epigenetic Anticancer Drugs
Anti-Cancer Agents in Medicinal Chemistry Approaches to Improve Efficiency of Dendritic Cell-based Therapy of High Grade Gliomas
Current Pharmaceutical Design Targeting Focal Adhesion Kinase in Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry Effect of Drugs in Cells and Tissues by NMR Spectroscopy
Current Topics in Medicinal Chemistry Applications of Computed Tomography, Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy for Planning External Beam Radiotherapy
Current Medical Imaging HSP27: Mechanisms of Cellular Protection Against Neuronal Injury
Current Molecular Medicine Small Molecules with EGFR-TK Inhibitor Activity
Current Drug Targets Dendrimers in Photodynamic Therapy
Current Medicinal Chemistry Histone and Non-Histone Targets of Dietary Deacetylase Inhibitors
Current Topics in Medicinal Chemistry Bypassing Cancer Resistance by Antagonizing “Inhibitor of Apoptosis Proteins” (IAPs)
Current Signal Transduction Therapy Aquaporins and Glia
Current Neuropharmacology Luminescent Silica Nanoparticles for Cancer Diagnosis
Current Medicinal Chemistry The Synthesis and Use of Boronated Amino Acids for Boron Neutron Capture Therapy
Anti-Cancer Agents in Medicinal Chemistry Stimuli-Responsive Nanocarriers for Drug Delivery to the Central Nervous System
Current Nanoscience Drug Delivery Across the Blood-Brain Barrier
Current Drug Delivery Application of In Vivo Electroporation to Cancer Gene Therapy
Current Gene Therapy Current Advances in Vehicles for Brain Gene Delivery
Current Gene Therapy Multivariate Statistical Tools for the Evaluation of Proteomic 2D-maps:Recent Achievements and Applications
Current Proteomics Dependence of DPPH Radical Scavenging Activity of Dietary Flavonoid Quercetin on Reaction Environment
Mini-Reviews in Medicinal Chemistry